Search
pyrimethamine/sulfadoxine (Fansidar, Sudox)
Indications:
- prophylaxis & treatment of Plasmodium falciparum malaria when chloroquine-resistance is suspected
Contraindications: Caution:
1) discontinue use at 1st sign of rash
2) hemolysis occurs in patients with G6PD deficiency
Dosage:
1) Acute malaria:
- adults: 2-3 tabs PO
- children 9-14 years: 2 tabs PO
- children 4-8 years: 1 tab PO
- children 1-3 years: 1/2 tab PO
- 2-11 months: 1/4 tab PO
2) Malaria prophylaxis: 1 tab PO weekly.
Tablet: 25 mg pyrimethamine, 500 mg sulfadoxine.
Pharmacokinetics: elimination: kidney.
Adverse effects:
1) common (> 10%)
- megaloblastic anemia, leukopenia, thrombocytopenia, pancytopenia, photosensitivity, hypersensitivity, atrophic glossitis, ataxia, tremors, seizures, headache, vomiting, gastritis
2) less common (1-10%)
- Stevens-Johnson syndrome, hepatitis
3) uncommon (< 1%)
- crystalluria, thyroid dysfunction, erythema multiforme, toxic epidermal necrolysis, rash, anorexia, glossitis, hepatic necrosis, respiratory failure
4) hemolysis occurs in patients with G6PD deficiency
Interactions
drug adverse effects of antimalarials
Related
malaria
General
antimalarial
pharmacologic combination
Database Correlations
PUBCHEM cid=65404
References
- The Pharmacological Basis of Therapeutics, 9th ed.
Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
Components
pyrimethamine (Daraprim)
sulfadoxine (Fanasil)